Related Experiment Videos
Tests for equivalence or non-inferiority for paired binary data.
Jen-pei Liu1, Huey-miin Hsueh, Eric Hsieh
1Division of Biostatistics and Bioinformatics, National Health Research Institutes, Taipei, Taiwan.
Statistics in Medicine
|January 10, 2002
Summary
This study compares two statistical tests for assessing therapeutic equivalence using paired binary data. The restricted maximum likelihood estimation (RMLE)-based test offers better control of type I error than the sample-based Wald-type test.
Area of Science:
- Biostatistics
- Clinical Trial Design
- Medical Device Evaluation
Background:
- Therapeutic equivalence and non-inferiority assessments are crucial in medical diagnostics.
- Comparing paired binary endpoints often relies on confidence intervals for response rate differences.
- Existing methods may have limitations in accurately controlling statistical errors.
Purpose of the Study:
- To investigate and compare two asymptotic test statistics for assessing equivalence or non-inferiority.
- To evaluate the performance of Wald-type and RMLE-based tests for paired binary endpoints.
- To determine sample size requirements for establishing therapeutic equivalence.
Main Methods:
- Derivation of sample size and power functions for two asymptotic tests.
- Computation of type I error and power using exact probabilities.
- Comparison of a Wald-type (sample-based) test with a restricted maximum likelihood estimation (RMLE)-based test.
Main Results:
- The RMLE-based test demonstrates superior control over type I error compared to the sample-based test.
- A minimal sample size of 120 is required for establishing equivalence with a 0.15 symmetric limit.
- The RMLE-based test without continuity correction performs well at the boundary point.
Conclusions:
- The RMLE-based test is recommended for assessing therapeutic equivalence with paired binary endpoints due to its robust error control.
- Accurate sample size calculation is essential for reliable equivalence studies.
- The findings provide practical guidance for clinical trial design and data analysis.